{
    "nctId": "NCT00856492",
    "briefTitle": "S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer",
    "officialTitle": "A Randomized Phase II Trial of Weekly Nanoparticle Albumin Bound Paclitaxel (Nab-Paclitaxel) (NSC-736631) With or Without Bevacizumab, Either Preceded by or Followed by Q 2 Week Doxorubicin (A)and Cyclophosphamide (C) Plus Pegfilgrastim (PEG-G) as Neoadjuvant Therapy For Inflammatory and Locally Advanced HER-2/NEU Negative Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 215,
    "primaryOutcomeMeasure": "Number of Patients With Pathological Complete Response Rate",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically or pathologically confirmed breast cancer meeting one of the following criteria:\n\n  * Locally advanced disease (stage IIIB disease, stage IIB/IIIA, or stage IIIC disease)\n  * Inflammatory disease meeting the following two clinicopathologic criteria:\n\n    * Diffuse erythema AND edema (peau d'orange) of the breast involving the majority of the skin of the breast, i.e., more than 50%\n    * A biopsy demonstrating cancer either within the dermal lymphatics OR in the breast parenchyma itself\n* HER2/neu-negative tumor as demonstrated by 0 or 1+ (weak or no staining) by DAKO, IHC, or equivalent test OR no gene amplification by FISH\\*\n\n  * 2+ by DAKO or IHC allowed provided FISH\\* negative\n* NOTE: \\*A negative FISH test ratio is \\< 1.8 or FISH HER2 gene copy \\< 4.0; if only a positive or negative result is available from the FISH test, a negative result is acceptable for study entry\n* Hormone receptor status known\n\nPATIENT CHARACTERISTICS:\n\n* Menopausal status not specified\n* Zubrod performance status 0-2\n* Granulocyte count \\> 1,500/mm\\^3\n* ANC \u2265 1,500/mm\\^3\n* Platelet count \\> 100,000/mm\\^3\n* Hemoglobin 9.0 g/dL\n* Serum creatinine \u2264 1.5 times upper limit of normal (ULN)\n* Bilirubin \u2264 1.5 mg/dL\n* ALT and AST \u2264 3 times ULN\n* Alkaline phosphatase \u2264 2.5 ULN (unless bone metastasis is present in the absence of liver metastasis)\n* Urine protein:creatinine ratio \u2264 0.5 OR urine protein \\< 1,000 mg on 24-hour urine collection\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception\n* Able to take oral medications (e.g., no uncontrolled nausea, vomiting, or diarrhea, lack of physical integrity of the upper gastrointestinal tract, or malabsorption syndrome)\n* QTc \\< 500 msec by EKG\n* LVEF normal by MUGA or ECHO (for patients with hypertension or for patients \\> 60 years of age)\n* NYHA class II cardiac function by baseline ECHO/MUGA (for patients who have received central thoracic radiotherapy that included the heart in the radiotherapy port, or for patients who have a history of class II heart failure but are asymptomatic on treatment are eligible)\n* No history of stroke (cerebrovascular accident), transient ischemic attack, or cardiac event within the past 12 months, including any of the following:\n\n  * Myocardial infarction (including severe/unstable angina)\n  * Coronary/peripheral artery bypass graft\n  * Symptomatic congestive heart failure\n  * Pulmonary embolism\n* No poorly controlled hypertension, defined as recurrent or persistent (\u2265 24 hours) elevated blood pressure (i.e., systolic blood pressure \u2265 140 mm Hg and/or diastolic blood pressure \u2265 90 mm Hg)\n* No other malignancy within the past 5 years except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer\n* Peripheral neuropathy \\< grade 2\n\nPRIOR CONCURRENT THERAPY:\n\n* No prior tyrosine kinase inhibitors\n* More than 5 years since prior chemotherapy, radiotherapy, or biologic therapy (e.g., trastuzumab or bevacizumab) for invasive breast cancer\n* At least 7 days since prior hormonal therapy\n* At least 7 days since prior and no concurrent strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole) or grapefruit juice\n* No concurrent CYP3A4 inducers (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. John's wort)\n* No other concurrent therapy for the treatment of breast cancer except for bisphosphonates\n* No concurrent brachytherapy",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}